EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

QuantaMatrix Inc. (317690) fair value: what the stock is really worth

As of Oct 6, 2026: fair value of QuantaMatrix Inc. KRW 1,498, price KRW 2,315, upside -35.3%, quality 35 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR

QI Thin data Oct 3, 2026

QuantaMatrix Inc.

317690 · KQ

Weakest SetupStrongly overvalued and low quality.

Low debt
Expensive Growth (revenue 5y +16.9 %/yr in KRW)
Fair value 1,498 KRW · Strongly overvalued (−35.3%)
Quality 35/100
Negative free cash flow
Trails peers (1/7)
Narrow moat 9/100
Thin data
⚠ Dilution
Watch QuantaMatrix Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

22,000 KRW 1,988 KRW Fair Value 1,498 KRW May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range 1,988 KRW – 22,000 KRW · fair‑value band 988.62 KRW – 1,872 KRW · the 2,315 KRW price screens above the 1,498 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.

Follow QuantaMatrix in your weekly email

Every Wednesday you see whether QuantaMatrix is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

QuantaMatrix Inc. operates as an in-vitro diagnostics company in South Korea.

Show more

QuantaMatrix Inc. operates as an in-vitro diagnostics company in South Korea. Its products include dRAST, a direct and rapid antimicrobial susceptibility test for treating sepsis that provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture; QDST, a rapid phenotypic drug susceptibility testing system for tuberculosis; QPLEX Alz plus assay, an early diagnosis kit for Alzheimer's disease; and Quanti9 and QuantiGal, a prognostic prediction kit for cardiovascular diseases. QuantaMatrix Inc. was founded in 2010 and is based in Seoul, South Korea.

Stock analysis

QuantaMatrix Inc. (317690) currently trades at 2,315 KRW, while our model-based Fair Value estimate is 1,498 KRW, 35.3% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 988.62 KRW (bear) to 1,872 KRW (bull), the price of 2,315 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

QuantaMatrix Inc. reported revenue of 3.7B KRW in FY2025 versus 550M KRW in FY2021, a compound +60.9%/yr. Reported net income was −19.5B KRW in FY2025.

Key figures

Market cap 45.3B KRW (≈ $33.9M) · P/S ratio 12.8 · Return on equity −85.8% · Return on assets (EBIT) −52.3% · Operating margin −556% · Revenue (TTM) 3.4B KRW · Revenue growth (YoY) −28.7% · Free cash flow −15.7B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).

What moves the price

The share trades about 55% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −35%, 317690 screens richer than that median.

Fair Value models

Bear 988.62 KRW Fair Value 1,498 KRW Bull 1,872 KRW
Price 2,315 KRW · Upside -35.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 993.43 KRW 1,331 KRW 1,987 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 993.43 KRW 1,331 KRW 1,987 KRW 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 35/100

Of which business quality 35 · Market factors (momentum, volatility) 23

Profitability 1
Margins and returns on capital today
Quality Growth 85
Are margins and returns improving?
Cashflow 6
Earnings quality: real cash, not paper profit
Fin. Strength 67
Balance sheet, leverage, solvency risk
Investment 61
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 14
Price trend over the last 3–12 months (market factor)
52W Momentum 5
Distance to the 52-week high (market factor)
Net Issuance 10
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+47.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.9%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+72.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−878.0% (2020) → −422.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

317690 screens overvalued: fair value 35% below the price. Compare with Abbott Laboratories, →

Compare QuantaMatrix Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 335 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Bottom 25%
Fair Value upside −35.3% · Below median
Profitability
Return on assets −25.2% · Bottom 25%
Growth and dividend
Revenue growth −28.7% · Bottom 25%
Balance sheet
Debt / equity 0.39× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/S (TTM) 0.01× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 7
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 16
HEALTH (low debt)81 · sector 98
DIVIDEND (yield)0 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $100.10 $74.79 −25%
Medtronic plc MDT $86.38 $65.61 −24%
Stryker Corporation SYK $275.43 $302.97 +10%
Boston Scientific Corporation BSX $43.65 $48.02 +10%
Edwards Lifesciences Corporation EW $85.19 $81.94 −4%
DexCom, Inc DXCM $85.36 $93.90 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%
STERIS plc STE $208.93 $229.82 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

QuantaMatrix Inc. · Fair Value
1,498 KRW −35%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "QuantaMatrix Inc. Fair Value". https://www.fairvalue-calculator.com/stock/317690

Frequently asked questions

Is QuantaMatrix Inc. (317690) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 1,498 KRW versus a price of 2,315 KRW, about −35% upside (overvalued).
What is the fair value of 317690?
Our model-based fair value for QuantaMatrix Inc. is 1,498 KRW (as of Oct 3, 2026), built from audited fundamentals. The current price: 2,315 KRW.
What is the quality score of 317690?
QuantaMatrix Inc. has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for QuantaMatrix Inc. (317690)?
Our model-based price target is the fair value of 1,498 KRW (as of Oct 3, 2026) from 1 valuation models. Cautious scenario 988.62 KRW, optimistic scenario 1,872 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the QuantaMatrix Inc. stock forecast for 2026?
Our models put fair value at 1,498 KRW, about −35% upside versus a price of 2,315 KRW (overvalued). Cautious scenario 988.62 KRW, optimistic scenario 1,872 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of QuantaMatrix Inc. (317690)?
QuantaMatrix Inc. reported trailing-twelve-month revenue of about 3.4B KRW (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of QuantaMatrix Inc. (317690)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For QuantaMatrix Inc. it is 1,498 KRW per share (as of Oct 3, 2026), against a price of 2,315 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is QuantaMatrix Inc. stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 317690 trades above its calculated fair value: price 2,315 KRW, fair value 1,498 KRW, a gap of about −35% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 317690?
No. The price is what the market pays today (2,315 KRW); the fair value is what the company's own numbers justify (1,498 KRW). For QuantaMatrix Inc. the two are 817.10 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is QuantaMatrix Inc. worth?
The market values QuantaMatrix Inc. at about 45.3B KRW (market capitalisation, as of Oct 3, 2026). Per share that is 2,315 KRW; our models calculate a fair value of 1,498 KRW per share.
What do the bullish and bearish scenarios say about 317690?
Our models span a range for QuantaMatrix Inc.: cautious scenario 988.62 KRW, base 1,498 KRW, optimistic 1,872 KRW per share (as of Oct 3, 2026, price 2,315 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of QuantaMatrix Inc. (317690)?
Balance-sheet figures for QuantaMatrix Inc. (as of Oct 3, 2026): return on equity −85.8%, debt of 0.39 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is 317690 from its 52-week high?
QuantaMatrix Inc. trades at 2,315 KRW, about 55% below its 52-week high of 5,180 KRW and 16% above the low of 1,988 KRW (as of Oct 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1,498 KRW is for.
Which stocks are comparable to QuantaMatrix Inc.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is QuantaMatrix Inc. stock attractive at the current price?
The data as of Oct 3, 2026: price 2,315 KRW, calculated fair value 1,498 KRW (−35%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 317690 calculated?
We run QuantaMatrix Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,498 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.4 % above its aggregate fair value. QuantaMatrix Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of QuantaMatrix Inc. (317690)?
The closing price on Oct 6, 2026 was 2,315 KRW. Our model-based fair value is 1,498 KRW, about −35% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with QuantaMatrix Inc. right now?
The price sits above even our optimistic bull case (1,872 KRW). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (988.62 KRW to 1,872 KRW) leaves room in how you read the outcome.

Key figures of QuantaMatrix Inc.

How large is the market capitalisation of QuantaMatrix Inc. (317690)?
The market capitalisation of QuantaMatrix Inc. is 45.3B KRW (≈ $33.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of QuantaMatrix Inc. (317690)?
The price-to-sales ratio of QuantaMatrix Inc. is 12.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of QuantaMatrix Inc. (317690)?
The return on equity (ROE) of QuantaMatrix Inc. is −85.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of QuantaMatrix Inc. (317690)?
On an EBIT basis the return on assets of QuantaMatrix Inc. is −52.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of QuantaMatrix Inc. (317690)?
The operating margin of QuantaMatrix Inc. is −556% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at QuantaMatrix Inc. (317690)?
Revenue at QuantaMatrix Inc. is growing −28.7% versus a year earlier (3y avg +42.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does QuantaMatrix Inc. (317690) generate?
The free cash flow of QuantaMatrix Inc. is −15.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does QuantaMatrix Inc. (317690) carry?
The net debt of QuantaMatrix Inc. is 9.3B KRW (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch QuantaMatrix Inc. in the live analysis

One click puts QuantaMatrix Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.